Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Coso

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Bone Marrow Transplantation|March 3, 2015
Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not availableS Garciaz, L Castagna, R Bouabdallah, et al.
Bone Marrow Transplantation|June 4, 2015
Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not availableS Garciaz, L Castagna, R Bouabdallah, et al.
Bone Marrow Transplantation|February 14, 2006
Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remissionH de Lavallade, C Faucher, S Fürst, et al.
Bone Marrow Transplantation|November 3, 2015
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicityS Garciaz, D Coso, J-M Schiano de Collela, et al.
Bone Marrow Transplantation|February 26, 2008
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myelomaH de Lavallade, J El-Cheikh, C Faucher, et al.
Bone Marrow Transplantation|June 27, 2012
Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphomaR Crocchiolo, L Castagna, S Fürst, et al.
Leukemia|June 27, 2008
Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparisonM Mohty, H de Lavallade, J El-Cheikh, et al.
Leukemia|October 12, 1999
A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patientsR Bouabdallah, F Lefrère, C Rose, et al.
Leukemia|June 9, 1999
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patientsR Bouabdallah, A M Stoppa, J F Rossi, et al.
Bone Marrow Transplantation|February 8, 2018
Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCTL Castagna, R Boubdallah, S Furst, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Bone Marrow Transplantation|March 3, 2015
Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not availableS Garciaz, L Castagna, R Bouabdallah, et al.
Bone Marrow Transplantation|June 4, 2015
Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not availableS Garciaz, L Castagna, R Bouabdallah, et al.
Bone Marrow Transplantation|February 14, 2006
Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remissionH de Lavallade, C Faucher, S Fürst, et al.
Bone Marrow Transplantation|November 3, 2015
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicityS Garciaz, D Coso, J-M Schiano de Collela, et al.
Bone Marrow Transplantation|February 26, 2008
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myelomaH de Lavallade, J El-Cheikh, C Faucher, et al.
Bone Marrow Transplantation|June 27, 2012
Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphomaR Crocchiolo, L Castagna, S Fürst, et al.
Leukemia|June 27, 2008
Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparisonM Mohty, H de Lavallade, J El-Cheikh, et al.
Leukemia|October 12, 1999
A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patientsR Bouabdallah, F Lefrère, C Rose, et al.
Leukemia|June 9, 1999
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patientsR Bouabdallah, A M Stoppa, J F Rossi, et al.
Bone Marrow Transplantation|February 8, 2018
Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCTL Castagna, R Boubdallah, S Furst, et al.
Pageof 5